Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBI354
- Development stage
- Phase 3
- Lead developer
- Innovent Biologics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IBI354 is an innovative HER2-targeted antibody-drug conjugate (ADC) developed by Innovent Biologics using the proprietary SoloTx® platform. It consists of a humanized anti-HER2 monoclonal antibody (trastuzumab) conjugated to a potent topoisomerase I inhibitor (a camptothecin derivative) with a high drug-to-antibody ratio (DAR) of 8. This design allows for targeted delivery of the cytotoxic payload to HER2-expressing tumor cells, inducing DNA damage and cell death. IBI354 is currently being evaluated in Phase 3 clinical trials for platinum-resistant ovarian cancer and first-line HER2-positive breast cancer, demonstrating a favorable safety profile with reduced incidence of interstitial lung disease and peripheral neuropathy compared to other HER2 ADCs.
- Other names
- IBI-354-InnoVent-HER2-ADCIBI354-InnoVent-HER2-ADCIBI 354-InnoVent-HER2-ADC
02
Targets
TOP1 (DNA Topoisomerase I)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on IBI354.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBI354.